Insilico Medicine vs Recursion
A side-by-side comparison of Insilico Medicine and Recursion, two Science tools, drawn from Ignaite's continuously-verified listings.
Compared from listings verified as of
Insilico Medicine
ScienceGenerative AI drug discovery — the end-to-end Pharma.ai suite.
View Insilico MedicineAt a glance
| Attribute | Insilico Medicine | Recursion |
|---|---|---|
| Category | Science | Science |
| Pricing | PAID | PAID |
| License | Proprietary | Proprietary |
| Deployment | Cloud | Cloud |
| Platforms (differs) | Web, API | Web |
| Model support | Self-contained (on-device) | Self-contained (on-device) |
| Vendor (differs) | Insilico Medicine | Recursion Pharmaceuticals |
The honest brief
Insilico Medicine
Sells its full discovery pipeline as licensed software — pharma can run PandaOmics and Chemistry42 directly, not just via a partner-only program.
- End-to-end Pharma.ai software suite
- Used by most of the top-20 pharma
- First AI-designed drug into Phase 2
- $2.75B Eli Lilly partnership
- Enterprise-only, opaque pricing
- Built for pharma R&D, not general users
- No approved drug yet
- Heavy domain expertise required
Recursion
Runs a vast in-house automated wet lab generating millions of cell experiments weekly, feeding a 50+ petabyte dataset few rivals can match.
- Recursion OS with LOWE language layer
- Massive proprietary biology dataset
- Natural-language target and compound queries
- Public company with pharma partners
- No self-serve product or API
- Partner and internal use only
- Opaque pricing
- No approved drug yet